An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

The layoffs followed a March announcement by Health Secretary Robert F. Kennedy Jr., who called for a major department overhaul.

An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...

But Erickson, CEO of Horizon Healthin South Dakota, has serious concerns about how the Medicaid cuts embedded in the giant ...

Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

The Health and Human Services Department says the county’s Treatment Court program is ending due to an unfilled key staff ...

Business Insider spoke with 16 federal workers after the Supreme Court decision that will allow federal staff cuts to ...

The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the president seeks to promote, and could lead to a loss of American capital, inv… ...

The federal government is scaling back data collection used to calculate the inflation rate because of staff shortages. Economists warn that could make for less accurate cost-of-living measures.

For instance, staff cuts to the Overdose Data to Action program and the Opioid Overdose Prevention and Surveillance program will hamper former tracking efforts at the Centers for Disease Control ...

The US Food and Drug Administration will meet its drug approval targets this year despite cutting thousands of staff, the agency’s commissioner said.